Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

World News

Geneos cancer vaccine shrinks liver tumors in small trial

by April 8, 2024
April 8, 2024
Geneos cancer vaccine shrinks liver tumors in small trial

NEARLY a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a small, early trial saw their tumors shrink, US researchers reported on Sunday.

The result was roughly twice the response typically seen with immunotherapy alone, the researchers said.

Findings from the preliminary study, presented at the American Association for Cancer Research in San Diego and published in Nature Medicine, suggests that vaccines based on mutations only present in a patient’s tumor may boost the immune system’s ability to recognize and attack hard-to-treat cancers.

The findings, which must be confirmed in a larger trial, moves the industry another step closer to effective cancer vaccines, after many past failures, and may expand the types of cancers that such therapies can treat.

Partners Moderna and Merck and Co. and others have had promising results combining customized vaccines with immunotherapy to prevent skin cancer from returning in patients following surgery.

For the study, researchers used samples from patients’ tumors to build vaccines based on neoantigens — new mutations only present on an individual patient’s tumor. The goal was to train the immune system to attack and kill only these unique proteins, leaving healthy tissue unscathed.

Unlike skin cancer, which has many mutations for the body to recognize, liver cancer is considered a cold cancer because it contains fewer mutations, which has rendered immunotherapies less effective.

“This vaccine essentially educates the immune system to recognize antigens that it’s ignored,” said study leader Dr. Mark Yarchoan of Johns Hopkins Kimmel Cancer Center.

The study involved 36 patients with hepatocellular carcinoma, the most common form of liver cancer. Patients were given custom-made vaccines on top of Merck’s widely used immunotherapy Keytruda, the standard of care at the time.

Nearly a third of the patients treated with the combination therapy (30.1%) experienced tumor shrinkage, with three of those subjects having a complete response, meaning no detectable signs of the tumor remaining after a median follow-up of 21.5 months.

That compares with the typical response of about 12% to 18% in patients with liver cancer who receive immunotherapy alone.

“This certainly suggested that the vaccine actually added clinical efficacy,” Yarchoan said.

The most common adverse effect was mild injection site reactions. There were no serious adverse events.

Unlike many vaccine candidates based on messenger RNA (mRNA) technology, the Geneos treatment is a DNA vaccine in which the genetic code of the mutated proteins is injected into cells using a small electrical impulse. Each vaccine can target up to 40 mutated genes. — Reuters

previous post
How 3 European human rights cases could shape climate litigation
next post
New Zealand tightens visa rules amid near record migration

Related Posts

US pushes UN to back interim Gaza ceasefire

February 20, 2024

Aircraft shortages turn into cash bonanza for some...

May 31, 2024

US IRS trains tax-audit sights on personal use...

February 22, 2024

Taiwan to increase missile drills amid China threats

March 5, 2024

Japan’s crazy 1980s bubble a dim memory as...

February 22, 2024

UK home, business property insurance payouts hit $6...

April 15, 2024

Hague-based world court to hear arguments on Israeli...

February 19, 2024

Brazil prosecutor general decides not to charge Bolsonaro...

March 28, 2025

Volatile bitcoin falls from record high as crypto...

March 15, 2024

Purported leaks show global reach of China-sponsored hacking

February 23, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Elon Musk connects with indie Andrew Yang on billionaire former Trump ally’s third party push

      July 8, 2025
    • Bondi under siege after DOJ reveals no Epstein client list

      July 7, 2025
    • Over 158 million Americans voted in 2024 as Trump reclaimed the White House

      July 7, 2025
    • US ends terrorist designation of Syrian militant leaders

      July 7, 2025
    • Sen. Steve Daines says regime change is the best long-term plan in Iran

      July 7, 2025
    • Biden aides pushed for early debate to show off Biden’s ‘strength,’ expose Trump’s ‘weakness,’ book says

      July 7, 2025

    Categories

    • Business (1,296)
    • Politics (6,295)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved